BioCryst Extends Consulting Agreement with Former CFO

BioCryst ( (BCRX) ) just unveiled an update.

BioCryst Pharmaceuticals extended a Consulting Agreement with its former CFO, Anthony Doyle, to ensure a smooth transition in leadership. The agreement, effective April 9, 2025, and extended on May 31, 2025, will continue on a month-to-month basis after December 31, 2025, providing stability during the CFO transition.

The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s strong technical momentum and positive earnings call drive the score higher, despite financial instability. Regulatory successes and strategic leadership changes also support the score, but persistent net losses and negative equity pose significant risks.

To see Spark’s full report on BCRX stock, click here.

More about BioCryst

BioCryst Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases.

Average Trading Volume: 4,566,515

Technical Sentiment Signal: Buy

Current Market Cap: $2.25B

For detailed information about BCRX stock, go to TipRanks’ Stock Analysis page.